Late Treatment With Autologous Expanded Regulatory T Cell Therapy after Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation

Researchers established that delayed autologous Treg therapy was both feasible and safe, even 12 months after cell production. The findings presented a new treatment protocol for Treg therapy, potentially expanding its applications to other indications.